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![TNF-α-mediated inflammatory signaling in lymphatic endothelium. *A--E*: representative Western blots of protein samples from lymphatic endothelial cells (LECs) exposed to TNF-α (20 ng/ml) for 2, 24, and 96 h and probed with phosphorylated (p-) and total forms of IκB, NF-κB, Akt, and ERK. Experiments were carried out in triplicates. β-Actin was used as endogenous housekeeping control. Note that the same blot (which was probed with phospho- and total IκB-α antibodies) was then probed with β-actin. The blot was stripped in between each antibody testing. Quantitative values obtained from each experiment are shown below each blot. \**P* \< 0.05 vs. control (Con). *F*: induction of inflammatory cytokines in inflamed lymphatics. TNF-α induces key proinflammatory cytokines such as IL-1β, IL-6, monocyte chemoattractant protein 1 (MCP-1), c-*fos*, and macrophage inflammatory protein 2 (MIP-2), in LECs. LECs were treated for 24 h with TNF-α (20 ng/ml). Real-time quantification was carried out, and fold change relative to untreated control was calculated. Experiments were done in triplicates. Values are means ± SE \**P* \< 0.05. *G*: immunofluorescence image of activated NF-κB translocation into nucleus in LECs; 4′,6-diamidino-2-phenylindole (DAPI) was used for nuclear staining. Magnification × 40. Scale bar 50 = µm.](zh00062087230001){#F0001}

![miR-9 and TNF-α-mediated signaling and endothelial-mesenchymal transition (EndMT) in LECs. *A*: representative Western blots showing expression of VE-cadherin, N-cadherin, endothelial NO synthase (eNOS), and phosphorylated eNOS in LECs transfected with control miR, miR-9 mimics, and inhibitors. Values from 3 independent experiments were quantified and are shown below each blot. Note that the same blot (which was probed with VE cadherin, followed by N-cadherin, subsequently with phospho-eNOS and total eNOS antibodies) was then probed with β-actin. The blot was stripped in between each antibody testing. *B*: representative Western blots of protein samples from LECs exposed to TNF-α (20 ng/ml) for 2, 24, and 96 h showing corresponding levels of β-catenin, ZEB1, VE-cadherin, and N-cadherin. Results from experiments carried out in triplicates were quantified and are shown below each blot. Values are means ± SE \**P* \< 0.05. Note that the same blot \[which was probed for β-catenin, ZEB1, and cadherin (N-cadherin and VE-cadherin)\] was then probed with β-actin. The blot was stripped in between each antibody testing. *C*: bromodeoxyuridine (BrdU) assay for cell proliferation. LECs were treated with miR-9 mimics or inhibitors (100 nM) in the absence or presence of TNF-α (20 ng/ml) for 2 h, and relative absorbance was measured and plotted. Experiments were done in triplicates. *D*: XTT assay for cell viability. LECs were treated as described in *C*, and XTT was added for 4 h. Relative absorbance was measured and plotted. All experiments were done in triplicates. Values are means ± SE \**P* \< 0.05 vs. control miR. \#*P* \< 0.05 vs. miR-9 mimic.](zh00062087230002){#F0002}
